TRON-DAO
6.4.2022 09:40:09 CEST | Business Wire | Press release
TRON founder Justin Sun has recently purchased the complete set of the crypto artworks "Twelve Digital Zodiac Heads" at the Twelve Digital Zodiac Heads Special Auction hosted by Metapoly XM, a brand under Poly Auction (Xiamen).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220403005114/en/
The "Twelve Digital Zodiac Heads" is the one and only NFT art collection that draws inspiration from China's Zodiac Heads, which was purchased on March 31 at a hammer price of around ¥9,832,500. Shortly after the auction, Justin Sun stated to the public that he would donate this collection in the future for a broader audience to enjoy. It is also believed that one of the animal heads in this collection will soon be listed on APENFT Marketplace for auction and introduced as rare, special-breed horses into WIN NFT HORSE, a horse racing game co-launched by TRON, the APENFT Foundation, and WINKLink.
The twelve zodiac animals are an epitome of Chinese folk culture and the unique philosophy of the Chinese nation. According to traditional Chinese culture, every newborn is assigned an auspicious animal based on their birth year. These animals are unchangeable marks that follow each Chinese throughout their life. They serve as a bond to maintain the national feelings and the Chinese culture. And of all the physical embodiment of these symbols, the Twelve Old Summer Palace bronze heads are the most precious.
Gathering the twelve bronze heads in the metaverse marks another major endeavor made by digital technology, represented by blockchain, in the cultural and art sphere. In the context of social informatization and digitization, digital propagation and protection of traditional culture will embrace wider applications in order to reproduce time-honored artworks in the digital world and diversify people's experience in art appreciation.
As a trailblazer in digital technology, Justin Sun also has serious clout in the realm of top-notch art collections. Through clinching a myriad of artworks created both by art masters and emerging digital artists on major trading platforms, Justin has managed to build an empire incorporating art, investment, finance, and more. His collections include works by Pablo Picasso, Andy Warhol, Giacometti, Beeple, and Pak, the latter two being the two most valuable crypto artists worldwide. In addition, Justin Sun has donated a number of well-known works, including Le Nez and Femme nue couchée au collier(Marie-Thérèse) , to organizations such as the APENFT Foundation to support the development of digital art.
APENFT is backed by the underlying technology of top-notch blockchains TRON with support from the world's largest distributed storage system Bittorrent File System (BTFS), dedicated to promoting the creator economy and fostering the integration of finance, culture and art in Metaverse. Its APENFT Marketplace, based on the TRON, will also be launched shortly.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220403005114/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
